Richard Kim, M.D. Professor at University of South Florida Service Chief, Moffit Cancer Center

JOIN HERE!

Objectives:

• Assess role of standard treatment in first- and second-line treatment of biliary tract cancers
• Assess role and importance of molecular profiling
• Assess novel targeted treatments and immunotherapy for management of biliary tract cancers

FACULTY DISCLOSURES:
Dr. Kim has indicated that he has relevant financial relationship with commercial interests.
     Consultant: Taiho, Bayer, Exelixis, Eisai, Roche, Ipsen
     Speaker: Astra Zeneca, Incyte

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

All the relevant financial relationships for these individuals have been mitigated.

TARGET AUDIENCE:
Faculty, Primary Care Physicians, APRNs, PharmD

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.